Biomea Fusion, Inc.(BMEA)
Biotechnology
Oncology Biotech
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2025-12-15 | Erdtmann Rainer M See Remarks | Purchase | +30,000 | +4.33%723,027 | $1.43 | $42,999 | View SEC filing | |
| 2025-12-04 | Hitchcock Michael J.M. Interim CEO | Purchase | +100,000 | +666.67%115,000 | $0.99 | $99,180 | View SEC filing | |
| 2025-12-02 | Erdtmann Rainer M See Remarks | Purchase | +50,000 | +7.78%693,027 | $1.09 | $54,552 | View SEC filing | |
| 2024-10-01 | Hitchcock Michael J.M. Director | Purchase | +10,000 | +200.00%15,000 | $10.06 | $100,600 | View SEC filing | |
| 2024-06-12 | Valle Franco Chief Financial Officer | Purchase | +12,509 | +41.71%42,500 | $4.43 | $55,361 | View SEC filing | |
| 2023-06-02 | A2A Pharmaceuticals, Inc. 10% Owner | Sale | -125,000 | -3.45%3,500,000 | $34.11 | $4,263,915 | View SEC filing | |
| 2023-05-17 | A2A Pharmaceuticals, Inc. 10% Owner | Sale | -25,000 | -0.68%3,625,000 | $33.84 | $846,000 | View SEC filing | |
| 2023-05-10 | A2A Pharmaceuticals, Inc. 10% Owner | Sale | -250,000 | -6.41%3,650,000 | $34.30 | $8,575,030 | View SEC filing | |
| 2023-04-26 | A2A Pharmaceuticals, Inc. 10% Owner | Sale | -200,000 | -4.88%3,900,000 | $29.12 | $5,823,760 | View SEC filing | |
| 2023-04-06 | A2A Pharmaceuticals, Inc. 10% Owner | Sale | -200,000 | -4.65%4,100,000 | $31.25 | $6,250,000 | View SEC filing | |
| 2023-04-06 | A2A Pharmaceuticals, Inc. 10% Owner | Sale | +200,000 | +5.13%4,100,000 | $31.25 | $6,250,000 | View SEC filing | |
| 2023-04-03 | Cormorant Asset Management, LP 10% Owner | Purchase | +400,000 | +12.61%3,570,872 | $30.00 | $12,000,000 | View SEC filing | |
| 2023-02-10 | Erdtmann Rainer M President and COO | Purchase | +8,400 | +100.00%6,000 | $17.00 | $142,800 | View SEC filing | |
| 2022-11-16 | Hitchcock Michael J.M. Director | Purchase | +5,000 | +100.00%5,000 | $7.93 | $39,650 | View SEC filing | |
| 2022-11-14 | Valle Franco Chief Financial Officer | Purchase | +4,100 | +30.81%17,407 | $7.63 | $31,286 | View SEC filing | |
| 2022-08-19 | A2A Pharmaceuticals, Inc. 10% Owner | Purchase | -30,684 | -0.71%4,300,000 | $13.87 | $425,648 | View SEC filing | |
| 2022-07-25 | A2A Pharmaceuticals, Inc. 10% Owner | Sale | -34,658 | -0.79%4,330,684 | $11.21 | $388,516 | View SEC filing | |
| 2022-06-28 | A2A Pharmaceuticals, Inc. 10% Owner | Sale | -34,658 | -0.79%4,365,342 | $11.76 | $407,578 | View SEC filing | |
| 2022-01-18 | Valle Franco Chief Financial Officer | Purchase | +10,000 | +100.00%10,000 | $8.68 | $86,767 | View SEC filing | |
| 2021-09-21 | A2A Pharmaceuticals, Inc. 10% Owner | Purchase | +34,658 | +0.79%4,400,000 | $10.96 | $379,852 | View SEC filing | |
| 2021-09-21 | Stergiopoulos Sotirios Director | Purchase | +34,658 | +0.79%4,400,000 | $10.96 | $379,852 | View SEC filing | |
| 2021-08-25 | Erdtmann Rainer M President & COO | Purchase | +24,000 | +11.74%228,470 | $13.20 | $316,872 | View SEC filing | |
| 2021-08-25 | Butler Thomas Andrew CEO | Purchase | +24,000 | +11.74%228,470 | $13.20 | $316,872 | View SEC filing | |
| 2021-08-19 | Erdtmann Rainer M President & COO | Purchase | +204,470 | +100.00%204,470 | $16.15 | $3,301,795 | View SEC filing | |
| 2021-08-19 | Butler Thomas Andrew CEO | Purchase | +204,470 | +100.00%204,470 | $16.15 | $3,301,795 | View SEC filing |
1-25 of 26